2. Search Result
Search Result
Results for "

Systolic blood pressure

" in MedChemExpress (MCE) Product Catalog:

33

Inhibitors & Agonists

2

Peptides

1

Inhibitory Antibodies

5

Natural
Products

1

Isotope-Labeled Compounds

Cat. No. 상품명 Target 연구분야 Chemical Structure
  • HY-111372
    Finerenone
    Maximum Cited Publications
    7 Publications Verification

    BAY 94-8862

    		 Mineralocorticoid Receptor Cardiovascular Disease Metabolic Disease
    Finerenone (BAY 94-8862) is a third-generation, selective, and orally active nonsteroidal mineralocorticoid receptor (MR) antagonist (IC50 = 18 nM). Finerenone displays excellent selectivity versus glucocorticoid receptor (GR), androgen receptor (AR), and progesterone receptor (> 500-fold). Finerenone has the potential for cardiorenal diseases research, such as type 2 diabetes mellitus and chronic kidney disease .
    Finerenone
  • HY-B2209
    Hydroxocobalamin
    3 Publications Verification

    Vitamin B12a

    		 Endogenous Metabolite Neurological Disease Metabolic Disease
    Hydroxocobalamin (Vitamin B12a) is a cyanide antidote. Hydroxocobalamin can decrease the cell and plasma cyanide concentrations and increase survival rate in acute cyanide poisoning. Hydroxocobalamin can improve newborn Cbl-C defect-induced metabolic profile and neurocognitive outcome. Hydroxocobalamin can normalize Vitamin B12 deficiency. Hydroxocobalamin can induce acute kidney injury. Hydroxocobalamin can be used for the researches of metabolic and neurological disease .
    Hydroxocobalamin
  • HY-14744A
    Levamlodipine besylate
    2 Publications Verification

    (S)-Amlodipine besylate; Levoamlodipine besylate

    		 Calcium Channel MMP Cardiovascular Disease
    Levamlodipine ((S)-Amlodipine; Levoamlodipin) besylate is an orally active L-type calcium channel blocker and MMP-9 modulator with high permeability and retention properties. Levamlodipine besylate significantly enhances plaque stability and improves lipid profiles by reducing blood pressure, decreasing systolic blood pressure variability, and inhibiting MMP-9 expression in atherosclerotic plaques. Levamlodipine besylate not only alleviates cardiac and aortic hypertrophy and prevents renal atrophy, but also produces synergistic effects in blood pressure reduction and organ protection when combined with bisoprolol (HY-129029). Levamlodipine besylate exerts no significant inhibitory effect on abdominal aortic intimal hyperplasia. When excessively accumulated in the epidermis, Levamlodipine besylate may induce changes in keratin structure, impair the skin barrier and trigger inflammation; long-term use further exacerbates skin irritation caused by local administration. Levamlodipine besylate can be used in research related to hypertension and atherosclerosis .
    Levamlodipine besylate
  • HY-111372R
    Finerenone (Standard)

    BAY 94-8862 (Standard)

    		 Reference Standards Mineralocorticoid Receptor Cardiovascular Disease
    Finerenone (Standard) is the analytical standard of Finerenone. This product is intended for research and analytical applications. Finerenone (BAY 94-8862) is a third-generation, selective, and orally available nonsteroidal mineralocorticoid receptor (MR) antagonist (IC50=18 nM). Finerenone displays excellent selectivity versus glucocorticoid receptor (GR), androgen receptor (AR), and progesterone receptor (>500-fold). Finerenone has the potential for cardiorenal diseases research, such as type 2 diabetes mellitus and chronic kidney disease .
    Finerenone (Standard)
  • HY-W005255
    3-(3-Hydroxyphenyl)propionic acid

    		Endogenous Metabolite Cardiovascular Disease
    3-(3-Hydroxyphenyl)propionic acid (3HPPA) is an endothelium-dependent nitric oxide (NO) release promoter and endothelial nitric oxide synthase (eNOS) activator. 3-(3-Hydroxyphenyl)propionic acid activates eNOS to mediate vascular smooth muscle relaxation and enhances endothelial cell NO synthesis, inducing vasodilation and reducing peripheral vascular resistance. 3-(3-Hydroxyphenyl)propionic acid can dose-dependently reduce systolic and diastolic blood pressure in spontaneously hypertensive rats (SHR) without affecting cardiac contractility or heart rate. 3-(3-Hydroxyphenyl)propionic acid has antihypertensive and vascular protective effects and can be used in the prevention and treatment of cardiovascular diseases .
    3-(3-Hydroxyphenyl)propionic acid
  • HY-114782
    H-Tyr-Tyr-OH

    L-Tyrosyl-L-tyrosine

    		 Angiotensin-converting Enzyme (ACE) Cardiovascular Disease
    H-Tyr-Tyr-OH (L-Tyrosyl-L-tyrosine) is an antihypertensive peptide. H-Tyr-Tyr-OH inhibits angiotensin I-converting enzyme (ACE) with an IC50 value of 0.028 mg/mL. H-Tyr-Tyr-OH can be used for the research of high blood pressure .
    H-Tyr-Tyr-OH
  • HY-118060
    Dipeptide 2

    N-Valyltryptophan; Val-Trp

    		 Angiotensin-converting Enzyme (ACE) Calcium Channel NO Synthase Cardiovascular Disease
    Dipeptide 2 (N-Valyltryptophan) is an orally active, competitive angiotensin-converting enzyme (ACE) inhibitory peptide with an IC50 of 10.50 μM. Dipeptide 2 reduces intracellular Calcium ions. Dipeptide 2 significantly increases the content of NO, inhibits the production of ET-1, and induces the phosphorylation of eNOS. Dipeptide 2 decreases the systolic and diastolic blood pressure of spontaneously hypertensive rats .
    Dipeptide 2
  • HY-17611
    Etripamil

    MSP-2017; (-)-MSP-2017

    		 Calcium Channel Cardiovascular Disease Neurological Disease
    Etripamil (MSP-2017) is a short-acting, L-type calcium-channel antagonist. Etripamil inhibits calcium influx through slow calcium channels, thereby slowing AV node conduction and prolonging the AV node refractory period. Etripamil increases heart rate and decreases systolic blood pressure. Etripamil can be used in the study of paroxysmal supraventricular tachycardia (PSVT) .
    Etripamil
  • HY-14744
    Levamlodipine
    2 Publications Verification

    (S)-Amlodipine; Levoamlodipine

    		 Calcium Channel MMP Cardiovascular Disease Neurological Disease
    Levamlodipine ((S)-Amlodipine; Levoamlodipin) is an orally active L-type calcium channel blocker and MMP-9 modulator with high permeability and retention properties. Levamlodipine significantly enhances plaque stability and improves lipid profiles by reducing blood pressure, decreasing systolic blood pressure variability, and inhibiting MMP-9 expression in atherosclerotic plaques. Levamlodipine not only alleviates cardiac and aortic hypertrophy and prevents renal atrophy, but also produces synergistic effects in blood pressure reduction and organ protection when combined with bisoprolol (HY-129029). Levamlodipine exerts no significant inhibitory effect on abdominal aortic intimal hyperplasia. When excessively accumulated in the epidermis, Levamlodipine may induce changes in keratin structure, impair the skin barrier and trigger inflammation; long-term use further exacerbates skin irritation caused by local administration. Levamlodipine can be used in research related to hypertension and atherosclerosis .
    Levamlodipine
  • HY-111827
    S-1-Propenyl-L-cysteine
    5+ Cited Publications

    		 Histamine Receptor Cardiovascular Disease Others Metabolic Disease Inflammation/Immunology
    S-1-Propenyl-L-cysteine is a stereoisomer of S-allyl-l-cysteine, extracted from garlic, with immunomodulatory effects and reduces blood pressure in a hypertensive animal model . S-1-Propenyl-L-cysteine exhibits antioxidative efficacy through a NO-dependent BACH1 signaling pathway . S-1-Propenyl-L-cysteine is orally active.
    S-1-Propenyl-L-cysteine
  • HY-19664
    Pranidipine

    OPC-13340

    		 Calcium Channel NO Synthase Cardiovascular Disease
    Pranidipine (OPC-13340) is an orally active L-type voltage-dependent calcium channel (L-VDCC) blocker with a Ki value of 0.16 nM. Pranidipine inhibits calcium-induced contraction, suppresses slow-response action potentials, shortens action potential duration, reduces systolic and diastolic blood pressure, and exerts vasodilatory effects. Pranidipine enhances its vasodilatory effect by blocking NO decomposition. Pranidipine can be used in research related to essential hypertension, angina pectoris, myocardial infarction, and dilated cardiomyopathy .
    Pranidipine
  • HY-106103
    Seglitide

    MK-678; L-363586

    		 Somatostatin Receptor Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology
    Seglitide (MK-678) is an orally active, selective SSTR2 agonist and somatostatin analog. Seglitide also acts as a competitive Somatostatin receptor antagonist, with pA2 values of 6.50, 6.24 and 6.09 against SS14, SS25 and SS28, respectively. Seglitide produces only weak, transient inhibition of myocardial contractility in isolated right atria of guinea pigs. Seglitide inhibits glucagon secretion and reduces circulating insulin levels. Seglitide causes a sustained, reversible reduction in elevated systolic blood pressure in streptozotocin (HY-13753)-induced diabetic rats, but exerts no effect on spontaneously hypertensive rats. Seglitide induces membrane hyperpolarization and inhibits electrical excitability. Seglitide induces concentration-dependent contraction and significant desensitization in isolated distal colon of rats. Seglitide can be used in research related to hypertension complicated with insulin-dependent diabetes mellitus .
    Seglitide
  • HY-W414915
    Valsartan methyl ester

    CGP 48933 methyl ester

    		 Drug Derivative Angiotensin Receptor Cardiovascular Disease Cancer
    Valsartan (CGP 48933) methyl ester is the methyl ester derivative of Valsartan (HY-18204). Valsartan is a selective and orally active angiotensin II type 1 (AT1) receptor blocker (ARB) with potent antihypertensive and cardioprotective effects. Valsartan competitively binds to AT1 receptors, inhibiting the binding of angiotensin II to AT1 receptors, thereby blocking angiotensin II-mediated vasoconstriction, sodium retention, and myocardial hypertrophy signaling pathways. Valsartan reduces systolic blood pressure in L-NAME-induced hypertensive rats. Valsartan can be used for the study and treatment of arterial hypertension, hypertensive heart disease, and heart failure .
    Valsartan methyl ester
  • HY-16056
    Arbutamine

    		Adrenergic Receptor Cardiovascular Disease
    Arbutamine is a short-acting, potent and nonselective β-adrenoceptor agonist. Arbutamine stimulates cardiac β1-, tracheal β2-, and adiopocyte β3- adrenergic receptors. Arbutamine provides cardiac stress increases heart rate, cardiac contractility, and systolic blood pressure. Arbutamine can be used for cardiac stress agent .
    Arbutamine
  • HY-16056A
    Arbutamine hydrochloride

    		Adrenergic Receptor Cardiovascular Disease
    Arbutamine hydrochloride is a short-acting, potent and nonselective β-adrenoceptor agonist. Arbutamine hydrochloride stimulates cardiac β1-, tracheal β2-, and adiopocyte β3- adrenergic receptors. Arbutamine hydrochloride provides cardiac stress increases heart rate, cardiac contractility, and systolic blood pressure. Arbutamine hydrochloride can be used for cardiac stress agent .
    Arbutamine hydrochloride
  • HY-101554
    Guancydine

    Guancidine

    		 Adrenergic Receptor Cardiovascular Disease
    Guancydine (Guancidine) is an orally active antihypertensive agent and vasodilator. Guancydine antagonizes the pressor effects of Angiotensin and Norepinephrine (HY-13715). Guancydine induces vasodilation in renal, mesenteric and cranial vascular beds, reduces peripheral resistance, increases cardiac output and lowers arterial blood pressure. Guancydine increases renal and forearm blood flow, reduces renal and forearm vascular resistance, alters cardiac systolic time, and reverses myocardial hypertrophy in hypertensive rats. Guancydine is applicable for research related to hypertension .
    Guancydine
  • HY-14744D
    Levamlodipine besylate Hemipentahydrate

    		Calcium Channel MMP Cardiovascular Disease Neurological Disease
    Levamlodipine besylate Hemipentahydrate is an orally active L-type calcium channel blocker and MMP-9 modulator with high permeability and retention properties. Levamlodipine besylate Hemipentahydrate significantly enhances plaque stability and improves lipid profiles by reducing blood pressure, decreasing systolic blood pressure variability, and inhibiting MMP-9 expression in atherosclerotic plaques. Levamlodipine besylate Hemipentahydrate not only alleviates cardiac and aortic hypertrophy and prevents renal atrophy, but also produces synergistic effects in blood pressure reduction and organ protection when combined with bisoprolol (HY-129029). Levamlodipine besylate Hemipentahydrate exerts no significant inhibitory effect on abdominal aortic intimal hyperplasia. When excessively accumulated in the epidermis, Levamlodipine besylate Hemipentahydrate may induce changes in keratin structure, impair the skin barrier and trigger inflammation; long-term use further exacerbates skin irritation caused by local administration. Levamlodipine besylate Hemipentahydrate can be used in research related to hypertension and atherosclerosis .
    Levamlodipine besylate Hemipentahydrate
  • HY-120321
    DSR-71167

    		Mineralocorticoid Receptor Carbonic Anhydrase Cardiovascular Disease
    DSR-71167 is an orally active mineralocorticoid receptor (MR) antagonist with an IC50 of 0.26 μM. DSR-71167 exhibits weak carbonic anhydrase (CA) inhibitory activity with an IC50 of 19 μM. DSR-71167 can dose-dependently increase urinary sodium excretion in rat models and has a very low risk of hyperkalemia in potassium-loading rat models. DSR-71167 lowers systolic blood pressure in hypertensive rat models. DSR-71167 can be used for research on hypertension and heart failure .
    DSR-71167
  • HY-N1115
    Tubotaiwine

    (+)-Tubotaiwine; NSC 306222; Tubotaiwin

    		 Others Cardiovascular Disease
    Tubotaiwine ((+)-Tubotaiwine), an alkaloid, has beneficial effect on cadmium (Cd) induced hypertension in rats. Tubotaiwine regulates systolic, diastolic and mean arterial blood pressure of the Cd exposed rats. Tubotaiwine reduces arterial stiffness, inhibits of oxidative stress and increases vascular remodeling .
    Tubotaiwine
  • HY-106667
    DL 071IT

    		Adrenergic Receptor Cardiovascular Disease Endocrinology
    DL 071IT is a potent non-selective beta-adrenergic receptor blocker. DL 071IT exhibits intrinsic sympathomimetic activity and weak membrane stabilizing activity. DL 071IT reduces exercise heart rate and systolic blood pressure, and even significantly lowers resting heart rate .
    DL 071IT
  • HY-101390B
    Niguldipine

    		Calcium Channel Cardiovascular Disease
    Niguldipine is a calcium channel blocker with activity in regulating cardiovascular function. Niguldipine can reduce systolic and diastolic blood pressure, thereby increasing heart rate and cardiac output. Niguldipine exhibits dose-dependent and sustained increases in coronary blood flow. Niguldipine also increases perfusion in the kidneys and femoral arteries, but the effect is temporary and to a lesser extent. The effect of Niguldipine on myocardial metabolism is not significant .
    Niguldipine
  • HY-123226
    TA-606

    		Angiotensin Receptor Cardiovascular Disease
    TA-606 is a potent and orally active angiotensin II-receptor antagonist. TA-606 shows antihypertensive efficacy. TA-606 can be used for hypertension research .
    TA-606
  • HY-14744B
    Levamlodipine hydrochloride

    (S)-Amlodipine hydrochloride; Levoamlodipine hydrochloride

    		 Calcium Channel MMP Cardiovascular Disease
    Levamlodipine ((S)-Amlodipine; Levoamlodipin) hydrochloride is an orally active L-type calcium channel blocker and MMP-9 modulator with high permeability and retention properties. Levamlodipine hydrochloride significantly enhances plaque stability and improves lipid profiles by reducing blood pressure, decreasing systolic blood pressure variability, and inhibiting MMP-9 expression in atherosclerotic plaques. Levamlodipine hydrochloride not only alleviates cardiac and aortic hypertrophy and prevents renal atrophy, but also produces synergistic effects in blood pressure reduction and organ protection when combined with bisoprolol (HY-129029). Levamlodipine hydrochloride exerts no significant inhibitory effect on abdominal aortic intimal hyperplasia. When excessively accumulated in the epidermis, Levamlodipine hydrochloride may induce changes in keratin structure, impair the skin barrier and trigger inflammation; long-term use further exacerbates skin irritation caused by local administration. Levamlodipine hydrochloride can be used in research related to hypertension and atherosclerosis .
    Levamlodipine hydrochloride
  • HY-111827R
    S-1-Propenyl-L-cysteine (Standard)

    		Histamine Receptor Cardiovascular Disease Others Metabolic Disease Inflammation/Immunology
    S-1-Propenyl-L-cysteine (Standard) is the analytical standard of S-1-Propenyl-L-cysteine. This product is intended for research and analytical applications. S-1-Propenyl-L-cysteine is a stereoisomer of S-allyl-l-cysteine, extracted from garlic, with immunomodulatory effects and reduces blood pressure in a hypertensive animal model . S-1-Propenyl-L-cysteine exhibits antioxidative efficacy through a NO-dependent BACH1 signaling pathway . S-1-Propenyl-L-cysteine is orally active.
    S-1-Propenyl-L-cysteine (Standard)
  • HY-14744S
    Levamlodipine-d4

    (S)-Amlodipine-d4; Levoamlodipine-d4

    		 Isotope-Labeled Compounds Calcium Channel MMP Others
    Levamlodipine-d4 is the deuterium labeled Levamlodipine. Levamlodipine ((S)-Amlodipine; Levoamlodipin) is an orally active L-type calcium channel blocker and MMP-9 modulator with high permeability and retention properties. Levamlodipine significantly enhances plaque stability and improves lipid profiles by reducing blood pressure, decreasing systolic blood pressure variability, and inhibiting MMP-9 expression in atherosclerotic plaques. Levamlodipine not only alleviates cardiac and aortic hypertrophy and prevents renal atrophy, but also produces synergistic effects in blood pressure reduction and organ protection when combined with bisoprolol (HY-129029). Levamlodipine exerts no significant inhibitory effect on abdominal aortic intimal hyperplasia. When excessively accumulated in the epidermis, Levamlodipine may induce changes in keratin structure, impair the skin barrier and trigger inflammation; long-term use further exacerbates skin irritation caused by local administration. Levamlodipine can be used in research related to hypertension and atherosclerosis .
    Levamlodipine-d4
  • HY-14744C
    Levamlodipine hydrobromide

    (S)-Amlodipine hydrobromide; Levoamlodipine hydrobromide

    		 Calcium Channel MMP Cardiovascular Disease Others
    Levamlodipine ((S)-Amlodipine; Levoamlodipin) hydrobromide is an orally active L-type calcium channel blocker and MMP-9 modulator with high permeability and retention properties. Levamlodipine hydrobromide significantly enhances plaque stability and improves lipid profiles by reducing blood pressure, decreasing systolic blood pressure variability, and inhibiting MMP-9 expression in atherosclerotic plaques. Levamlodipine hydrobromide not only alleviates cardiac and aortic hypertrophy and prevents renal atrophy, but also produces synergistic effects in blood pressure reduction and organ protection when combined with bisoprolol (HY-129029). Levamlodipine hydrobromide exerts no significant inhibitory effect on abdominal aortic intimal hyperplasia. When excessively accumulated in the epidermis, Levamlodipine hydrobromide may induce changes in keratin structure, impair the skin barrier and trigger inflammation; long-term use further exacerbates skin irritation caused by local administration. Levamlodipine hydrobromide can be used in research related to hypertension and atherosclerosis .
    Levamlodipine hydrobromide
  • HY-W738639
    18-Hydroxy-11-deoxy corticosterone

    18-OH-DOC; 11-Deoxy-18-hydroxycorticosterone

    		 Melanocortin Receptor Angiotensin Receptor Drug Metabolite Mineralocorticoid Receptor Cardiovascular Disease Metabolic Disease
    18-Hydroxy-11-deoxy corticosterone (18-OH-DOC) is a mineralocorticoid whose synthesis is regulated by adrenocorticotropic hormone (ACTH) and angiotensin II. 18-Hydroxy-11-deoxy corticosterone is an intermediate in the metabolism of progesterone and plays an important role in regulating blood pressure and water-salt balance. Continuous infusion of 18-Hydroxy-11-deoxy corticosterone can increase systolic blood pressure in rats, and plasma levels of 18-Hydroxy-11-deoxy corticosterone are significantly elevated in the db/db mouse model of type 2 diabetes, suggesting its potential involvement in metabolic dysregulation and diabetes-related regulation. 18-Hydroxy-11-deoxy corticosterone holds promise for research in areas such as hypertension, diabetes, and other related fields .
    18-Hydroxy-11-deoxy corticosterone
  • HY-W414915R
    Valsartan methyl ester (Standard)

    CGP 48933 methyl ester (Standard)

    		 Reference Standards Drug Derivative Angiotensin Receptor Cardiovascular Disease
    Valsartan (CGP 48933) methyl ester (Standard) is the analytical standard of Valsartan methyl ester (HY-W414915). This product is intended for research and analytical applications. Valsartan methyl ester is the methyl ester derivative of Valsartan (HY-18204). Valsartan is a selective angiotensin II type 1 (AT1) receptor blocker (ARB) with potent antihypertensive and cardioprotective effects. Valsartan competitively binds to AT1 receptors, inhibiting the binding of angiotensin II to AT1 receptors, thereby blocking angiotensin II-mediated vasoconstriction, sodium retention, and myocardial hypertrophy signaling pathways. Valsartan reduces systolic blood pressure in L-NAME-induced hypertensive rats. Valsartan can be used for the study and treatment of arterial hypertension, hypertensive heart disease, and heart failure .
    Valsartan methyl ester (Standard)
  • HY-180354
    Mopidralazine hydrochloride

    MDL-899

    		 Drug Derivative Cardiovascular Disease
    Mopidralazine hydrochloride (MDL-899) (Compound 30) is an orally active antihypertensive agent. Mopidralazine hydrochloride significantly reduces systolic blood pressure (ED50 = 1.94 mg/kg) in spontaneously hypertensive rats models. Mopidralazine hydrochloride has a slower onset of action but a longer duration of action and has a significantly smaller effect on increasing heart rate in canine model of renal hypertension. Mopidralazine hydrochloride can be used for the research of hypertension .
    Mopidralazine hydrochloride
  • HY-W343043
    Pyrazinoylguanidine

    PZG

    		 Drug Derivative Cardiovascular Disease Metabolic Disease
    Pyrazinoylguanidine (PZG) is an analogue of the potassium sparing diuretic, Amiloride (HY-B0285). Pyrazinoylguanidine can lower the systolic and diastolic blood pressure of patients with primary hypertension, has a certain effect on reducing heart rate, and does not affect the concentrations of electrolytes such as sodium, potassium, and chloride in the blood serum. Pyrazinoylguanidine can reduce the hyperglycemia and hyperinsulinemia in type 2 diabetes, reduce the levels of triglycerides, cholesterol, and free fatty acids, and reverse the hyperglycemia and hyperlipidemia induced by thiazide diuretics, such as Hydrochlorothiazide (HY-B0252). Pyrazinoylguanidine ican nhibit the reabsorption of urea by the renal tubules, thereby increasing the clearance rate and excretion volume of urea, reducing the serum urea concentration, and minimizing its toxic accumulation .
    Pyrazinoylguanidine
  • HY-113858A
    Brefonalol (hydrochloride)

    Brefanolol hydrochloride

    		 Adrenergic Receptor Cardiovascular Disease
    Brefonalol (Brefanolol) hydrochloride is an orally active, non-selective β-adrenergic receptor blocker with vasodilatory properties. Brefonalol hydrochloride exhibits an optimal balance between β-blockade and vasodilatory effects at low doses: it reduces blood pressure and slows heart rate, while increasing stroke volume instead of decreasing it, causing no significant elevation in peripheral resistance and increasing reactive hyperemia; at high doses, the β-blockade effect dominates. Brefonalol hydrochloride can be used in the research of arterial hypertension .
    Brefonalol (hydrochloride)
  • HY-105111
    P-536

    		Parasite Angiotensin-converting Enzyme (ACE) HSV DNA/RNA Synthesis Cardiovascular Disease Metabolic Disease
    P-536 is a ACE inhibitor that also inhibits herpes simplex virus HSV-1 thymidine kinase and Trypanosoma cruzi RNA polymerase. By inhibiting the renin-angiotensin system, downregulating the expression of AT1R and NOX4, and reducing oxidative stress (decreasing plasma hydrogen peroxide (H2O2) and 8-isoprostaglandin levels), P-536 effectively reduces systolic blood pressure and improves vascular reactivity. P-536 also inhibits the replication of DNA/RNA viruses such as HSV-1 by blocking nucleotide metabolism and nucleic acid synthesis, competitively inhibits RNA synthesis in Trypanosoma cruzi, and inhibits amastigote replication, thereby impeding its growth. P-536 is suitable for research on hypertension, insulin resistance, and Chagas disease .
    P-536
  • HY-P992108
    Efadirelaxin alfa

    RELAX10

    		 RXFP Receptor Akt NO Synthase VEGFR Cardiovascular Disease
    Efadirelaxin alfa (RELAX10) is a highly selective agonist of relaxin/insulin-like family peptide receptor RXFP1. After subcutaneous administration in animal experiments, Efadirelaxin alfa exhibits a significantly prolonged terminal half-life (7 days in mice, 3.75 days in rats), and shows no activity against related receptors such as RXFP2 and RXFP3. Efadirelaxin alfa has significant anti-cardiac hypertrophy and anti-fibrotic effects. Efadirelaxin alfa effectively attenuates and reverses cardiac hypertrophy and collagen deposition by regulating the TGF-β1/Smad2 and AKT/eNOS signaling pathways. Efadirelaxin alfa improves cardiac systolic function without causing fluctuations in blood pressure or heart rate, demonstrating favorable safety. Efadirelaxin alfa is currently mainly used in studies related to heart failure .
    Efadirelaxin alfa

온라인 문의

Your information is safe with us. * Required Fields.

호칭

  

Country or Region *

고객명 *

 

회사명 *

Department *

     

메일주소 *

 

상품명 *

Cat. No.

  

Requested quantity *

전화번호 *

     

비고

온라인 문의

Inquiry Information

상품명:
Cat. No.:
수량:
MCE Japan Authorized Agent: